

Case Study

GlucosePATH shows the way to improved outcomes and \$1.1MM in employer drug cost savings



Background

A self-insured company has 600 employees with Type 2 Diabetes

The company asked if GlucosePATH could help improve employee HbA1c outcomes and reduce the company's prescription medicine costs

GlucosePATH Overview

Evaluates up to 6 million combinations of medications per patient

Considers patient and system costs in decisions

FDA review completed August 2017

Clinical trial at Saint Elizabeth Healthcare October 2016 to January 2018

Reduces patient average HbA_{1c} by 0.6 in 90 days (n=, p<0.02)

Approximately 63% of study patients follow PATH recommendations

Analysis


Data and Methods:

- Company's 620 employees represented by sample of 200 patients currently under PCP supervision
- GlucosePATH evaluated current PCP medication regimens for:
 - HbA1c control
 - Patient cost
 - System cost
 - Composite scores (weight gain, hypoglycemia risks, etc.)
- Regimen meds mapped to employer formulary (e.g., Levemir to Lantus)
- Employees allowed use of manufacturer coupons

PCP 200-Patient Summary


GlucosePATH estimated the Company spends \$1.73MM annually on Type 2 medication. Average HbA1c is 7.8g. Other outcomes are mixed.

| Population Metrics (PCP) | Average |
|--------------------------|----------|
| A1c | 7.89 |
| System Cost per Month | \$233 |
| Patient Cost per Month | \$20 |
| Composite PATH Score | 35.0 |
| Annual System Spend | \$1.73MM |




PCP System Cost vs HbA1c control

Monthly System Cost and a1c Levels
PCP Therapies - Population



PCP Patient Cost vs HbA1c control


Monthly Patient OOP Cost and a1c Levels
PCP Therapies - Population



GlucosePATH Analysis and Recommendations

PATH solutions improve HbA1c, lower system costs, and provide more side effect benefits.

| Population Metrics (PATH) | Averages |
|---------------------------|---------------|
| A1c | 6.7 (-1.2) |
| System Cost per Month | \$76 (-\$157) |
| Patient Cost per Month | \$20 (same) |
| Composite PATH Score | 84.0 (+49) |
| Annual Savings | \$1.17MM |
| Annual Savings (63% par) | \$737K |




PCP and PATH System Cost vs HbA1c control

Monthly System Cost and a1c Levels

PCP and PATH Therapies - Population


- ◆ PCP System Costs
- PATH System Costs



PCP and PATH Patient Cost vs HbA1c control

Monthly Patient OOP Cost and a1c Levels
PCP and PATH Therapies - Population

◆ Patient Monthly OOP Cost
■ PATH Patient OOP Costs



PATH Recommendations

Keys to managing system costs for better outcomes:

- Software makes consistent pay-for-performance decisions around formulary cost and efficacy
- Manufacturer coupons matter
- A small patient sub-population requires special attention